Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.63 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.57 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18605999 | 1.00 | KCNH2 (0.63) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL30608946 | 0.93 | TLR8 (0.67) | KCNH2TLR8TLR7 | |
| SCHEMBL18109655 | 0.93 | TLR8 (0.67) | KCNH2TLR8TLR7 | |
| SCHEMBL18109656 | 0.93 | TLR8 (0.67) | KCNH2TLR8TLR7 | |
| SCHEMBL19723035 | 0.91 | KCNH2 (0.58) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL13975711 | 0.85 | KCNH2 (0.85) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL13975710 | 0.85 | KCNH2 (0.85) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL19723066 | 0.85 | KCNH2 (0.85) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL13975548 | 0.83 | CYP2D6 (0.61) | KCNH2TLR8TLR7CYP2D6DRD1 | |
| SCHEMBL13975543 | 0.83 | KCNH2 (0.65) | KCNH2TLR8TLR7CYP2D6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| EP-3321265-B1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10285990-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180263985-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2018-09-20 | — | — | US | disclosed |
| EP-3321265-A1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | Gilead Sciences, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3097102-B1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-8916575-B2 | Quinazoline derivatives for the treatment of viral infections and further diseases | JANSSEN R&D IRELAND (IE) | 2014-12-23 | — | — | US | disclosed |
| US-8916575-B2 | Quinazoline derivatives for the treatment of viral infections and further diseases | JANSSEN R&D IRELAND (IE) | 2014-12-23 | — | — | US | disclosed |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-03-13 | — | — | US | disclosed |
| WO-2012156498-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | KCNH2 4348/4885TLR8 1/4885TLR7 9/4885 |
| US-20180263985-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | KCNH2 4796/4885TLR8 1/4885TLR7 4/4885 |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | TLR3, TLR5, TLR4 | KCNH2 2625/4885TLR8 9/4885TLR7 6/4885 |
| US-10285990-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | KCNH2 4348/4885TLR8 1/4885TLR7 9/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | KCNH2 4348/4885TLR8 1/4885TLR7 9/4885 |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | KCNH2 4348/4885TLR8 1/4885TLR7 9/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | KCNH2 4348/4885TLR8 1/4885TLR7 9/4885 |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | KCNH2 4796/4885TLR8 1/4885TLR7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.